"Designing Growth Strategies is in our DNA"

Hyperglycemia Treatment Market Size, Share, and COVID-19 Impact Analysis By Treatment (Fluid Replacement, Electrolyte Replacement, Insulin Therapy, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies and Online & Retail Pharmacies), and Regional Forecast, 2024-2032

Region :Global | Report ID: FBI107780 | Status : Ongoing

 

KEY MARKET INSIGHTS

Hyperglycemia is the early stage of diabetes which poses a major threat to human health if not managed. Also, diabetes patients may develop hyperglycemia if they do not control their blood sugar levels or skip a dose of their medication, among other factors. The increasing prevalence of diabetes, especially in emerging countries like India, China, Brazil, etc., is resulting in the rising incidence of hyperglycemia in these countries.



  • According to the data published by the International diabetes federation (IDF) in 2021, it was reported that around 74.0 million adults are living with diabetes in India.


The increasing prevalence of hyperglycemia globally is attributed to the shift towards sedentary lifestyles, especially in countries like the U.S., India, China, etc. The major players in the market are focusing on developing new drugs to offer effective treatment options to meet the growing demand from diabetes patients worldwide. This has led to increasing research & development investments to introduce new treatment methods in this market.


  • According to the data published by Mary Ann Liebert, Inc., in 2020, it was reported that the prevalence of hyperglycemia is around 36.0% in people of age 18-54 years in the U.S.


However, the potential for adverse reactions while taking insulin or other drugs to treat hyperglycemia is limiting the market expansion. In addition to others, using insulin may have side effects such as edema, muscle cramps, itchiness at the injection site, and rapid weight gain. Patients who inject more insulin than necessary may also cause low blood sugar, which, if left untreated, might result in a coma. All these factors are further responsible for limiting the market growth.

Impact of COVID-19 on the Hyperglycemia Treatment Market


The COVID-19 pandemic has been challenging for the major players in the market as they encountered challenges supplying medications to various countries as a result of a disrupted supply chain due to the various government guidelines and imposed lockdown.

Apart from this, the pandemic offered various opportunities for pharmaceutical companies to develop new drugs for hyperglycemia and expand their pipeline portfolio. Various pharmaceutical companies collaborated with other players to manufacture and develop new treatment options for hyperglycemia.


  • For example, in May 2022, Eli Lilly and Company received U.S. FDA approval for a Mounjaro injection to control high blood sugar levels in type-2 diabetes patients used along with following proper diet and exercise.


Additionally, the pandemic has increased the number of people receiving home care treatment, including insulin therapy, medications, and lifestyle adjustments to manage hyperglycemia effectively.

Key Insights


The report will cover the following key insights:


  • Prevalence of Diabetes, By Key Countries, 2022.

  • New Product Launches, By Key Players.

  • Key Industry Developments- Mergers, Partnerships, & Acquisitions.

  • Impact of COVID-19 on the Market.


Analysis by Treatment


Based on treatment, the market is segmented into fluid replacement, electrolyte replacement, insulin therapy, and others. The increasing focus of key players in research & development investments to develop and launch new insulin products used to treat hyperglycemia effectively is responsible for driving the insulin therapy segment growth. This along with the focus of industry players collaborating with other companies to obtain the distribution rights of drugs that are used to control hyperglycemia to market them in developing and under-developing countries.


  • In August 2022, Eris Lifesciences, an Indian pharmaceutical company, entered into a licensing agreement with Biocon Biologics, a biotechnology company, to market insulin glargine in India. The launch of insulin glargine is expected to take place in 2023. Insulin glargine is a modified form of human insulin used to manage both type 1 and type 2 diabetes.


Regional Analysis


To gain extensive insights into the market, Request for Customization


North America dominates the hyperglycemia treatment market due to the ongoing clinical trials on various drugs, advanced healthcare infrastructure in the U.S. and Canada, and the increasing number of pharmaceutical companies. Additional factors contributing to the market growth include the rising approval of new products by regulatory bodies across North America.

Asia Pacific is anticipated to grow at a faster pace during the forecast period. This is due to the presence of a large patient population suffering from diabetes and the growing adoption of new treatment options in countries like China, India, etc., which is further responsible for the market growth in this region.


  • For example, in December 2022, Glenmark Pharmaceuticals launched a triple fixed-dose combination of teneligliptin with pioglitazone and metformin for type-2 diabetes patients in India.


Key Players Covered


The report will include the profiles of key players such as Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Novo Nordisk A/S, Bristol-Myers Squibb Company, Sanofi, AstraZeneca, Teva Pharmaceutical Industries Ltd., and others.

Segmentation


















By Treatment


By Route of Administration


By Distribution Channel


By Geography



  • Fluid Replacement

  • Electrolyte Replacement

  • Insulin Therapy

  • Others




  • Oral

  • Parenteral




  • Hospital Pharmacies

  • Online & Retail Pharmacies




  • North America (U.S., Canada)



  • Europe (U.K., Germany, France, Spain, Italy, Scandinavia and the Rest of Europe)

  • Asia Pacific (Japan, Australia, China, India, Southeast Asia and the Rest of APAC)

  • Latin America (Brazil, Mexico and the Rest of LATAM)

  • Middle East & Africa (GCC, South Africa, Rest of MEA)



Key Industry Developments



  • December 2022: Abbott announced that its FreeStyle Libre 3 sensor can now be used with the mylife Loop solution from partners Ypsomed and CamDiab. This integration creates an automated system for delivering insulin based on real-time glucose data. This Automated Insulin Delivery (AID) solution is available in Germany and will be rolled out to other European countries starting in 2023.

  • October 2022: Glenmark Pharmaceuticals Limited launched the Lobeglitazone drug in India for type 2 diabetes patients who are resistant to insulin. This drug improves sugar levels in uncontrolled diabetics and offers treatment for insulin resistance patients in India.

  • January 2020: Novo Nordisk A/S received U.S. FDA approval for Fiasp insulin injection. This injection is used for treating children with diabetes and is available for adults in three different dosing options.

  • In November 2019, Sanofi announced the positive results in phase 3 clinical trials of Toujeo, an insulin glargine injection for children and adolescents aged 6-17 years with type 1 diabetes.





  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Grifols
Styker
3M
uniliver
Jubilant

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X